期刊
CONTEMPORARY CLINICAL TRIALS
卷 113, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cct.2022.106679
关键词
Anal cancer prevention; Persons living with HIV; Clinical trial design
资金
- National Cancer Institute of the National Institutes of Health [UM1CA121947]
It is known that people living with HIV have a higher risk of anal HSIL and anal cancer compared to those without HIV. A randomized trial conducted by the AIDS Malignancy Consortium aimed to compare preventive strategies for anal cancer among PLWH with anal HSIL. The study design of the ANCHOR trial, which estimates the anal cancer event rate in this high-risk population, is described in this paper.
It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high as 14.1% among PLWH compared with 3.2% among those who are not living with HIV. To address these concerns, the AIDS Malignancy Consortium completed a large-scale, randomized trial to compare strategies for the prevention of anal cancer among PLWH with anal HSIL. The objective of the study was to determine whether treating anal HSIL was effective in reducing the incidence of anal cancer in PLWH compared with active monitoring. This paper describes the design of the ANal Cancer/HSIL Outcomes Research Study (ANCHOR) with respect to estimating the anal cancer event rate in this high risk population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据